MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-12-2026
Alnylam Pharmaceuticals Accounts Receivables 2011-2026 | ALNY
Accounts receivable — is the amount of money owed to a company by other organizations, individuals, or the government. It arises when a company has already delivered goods, performed work, or provided services, but has not yet received payment for them.Examples of accounts receivable
- Customers have not paid invoices for delivered products
- An advance has been paid to a supplier, but goods have not yet been received
- Employees have not reported on accountable amounts
- The government must refund tax overpayments
- Outstanding loans issued
- Asset quality
Accounts receivable are part of current assets. But they are not cash — they are promises. Investors assess how realistic these promises are to be collected. The higher the share of overdue or doubtful receivables, the greater the risk of asset impairment. - Impact on cash flow
Even if a company shows a profit, the money can be "tied up" in receivables. This means profit does not turn into actual cash, and the company may face liquidity shortages. - Assessment of management efficiency
The following accounts receivable turnover ratios are commonly used:
Receivables turnover = Revenue / Average accounts receivable
(the higher — the better)
Days Sales Outstanding (DSO) = 365 / Turnover
(the fewer days — the faster customers pay)
If the DSO is constantly increasing — this is a red flag — customers are delaying payments, and money gets stuck in settlements.
Annual Accounts Receivables Alnylam Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 778 M | 405 M | 99.6 M | 32.3 M | 73.3 M | 33.5 M | 14.9 M | 18.8 M | 34 M | 23.3 M | 8.3 M | 39.9 M | 4.25 M | 104 K | 1.47 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 778 M | 104 K | 104 M |
Quarterly Accounts Receivables Alnylam Pharmaceuticals
| 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 567 M | 418 M | 405 M | 354 M | 309 M | 321 M | 328 M | 325 M | 221 M | 219 M | 238 M | 21.9 M | - | 23.4 M | 73.3 M | 23.6 M | 33.9 M | 19.1 M | 33.5 M | 33.5 M | 33.5 M | 33.5 M | 14.9 M | 14.9 M | 14.9 M | 14.9 M | 5.62 M | 5.62 M | 5.62 M | 5.62 M | 34 M | 14.6 M | 15.4 M | 34 M | 23.3 M | 23.3 M | 23.3 M | 23.3 M | 8.3 M | 8.3 M | 8.3 M | 8.3 M | 39.9 M | 39.9 M | 39.9 M | 39.9 M | 4.25 M | 4.25 M | 4.25 M | 4.25 M | 104 K | 104 K | 104 K | 104 K | 1.47 M | 1.47 M | 1.47 M | 1.47 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 567 M | 104 K | 79.4 M |
Accounts Receivables of other stocks in the Biotechnology industry
| Issuer | Accounts Receivables | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Precigen
PGEN
|
3.92 M | $ 3.1 | -0.96 % | $ 758 M |  USA |
 |
I-Mab
IMAB
|
130 M | - | - | $ 866 M |  China |
 |
Albireo Pharma
ALBO
|
3.27 M | - | -0.23 % | $ 916 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
144 M | $ 19.57 | 1.77 % | $ 915 M | USA |
 |
AgeX Therapeutics
AGE
|
57 K | - | -10.17 % | $ 12.2 K | USA |
 |
Aptinyx
APTX
|
257 K | - | -39.0 % | $ 4.57 M | USA |
 |
Acorda Therapeutics
ACOR
|
17.3 M | - | -24.86 % | $ 820 K | USA |
 |
Acasti Pharma
ACST
|
802 K | - | 4.01 % | $ 150 M |  Canada |
 |
Adverum Biotechnologies
ADVM
|
886 K | - | - | $ 86.2 M | USA |
 |
Advaxis
ADXS
|
234 K | - | -9.65 % | $ 45.9 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
234 K | - | - | $ 7.46 M |  Israel |
 |
Autolus Therapeutics plc
AUTL
|
109 K | $ 1.33 | 0.76 % | $ 339 M |  Britain |
 |
BeiGene, Ltd.
BGNE
|
865 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
bluebird bio
BLUE
|
300 K | - | - | $ 546 M | USA |
 |
BioDelivery Sciences International
BDSI
|
56.9 M | - | -4.8 % | $ 255 M | USA |
 |
Cara Therapeutics
CARA
|
2.76 M | - | -3.03 % | $ 260 M | USA |
 |
ChemoCentryx
CCXI
|
411 K | - | - | $ 3.74 B | USA |
 |
Avid Bioservices
CDMO
|
16.6 M | - | - | $ 789 M | USA |
 |
CRISPR Therapeutics AG
CRSP
|
25 M | $ 47.09 | 1.42 % | $ 4.23 B |  Schweiz |
 |
Arbutus Biopharma Corporation
ABUS
|
1.45 M | $ 4.53 | 5.1 % | $ 868 M | Canada |
 |
AIkido Pharma
AIKI
|
200 K | - | 1.93 % | $ 17.4 M | USA |
 |
Brickell Biotech
BBI
|
1.13 M | - | -5.38 % | $ 6.06 M | USA |
 |
CytomX Therapeutics
CTMX
|
2.01 M | $ 4.22 | -0.47 % | $ 582 M | USA |
 |
Calithera Biosciences
CALA
|
1.54 M | - | -10.95 % | $ 876 K | USA |
 |
Alpine Immune Sciences
ALPN
|
392 K | - | - | $ 2.17 B | USA |